Chief Medical Officer (5) · 4D Molecular Therapeutics, Inc. (FDMT)

Robert Fishman

FY2020 is the first fiscal year CompBrief holds for Robert Fishman as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$3,339,803

Salary $89,749Stock awards $0Bonus $50,000

1st of 3 named executive officers at 4D Molecular Therapeutics by FY2020 total.

3 named officers on file for 4D Molecular Therapeutics, FY2020

Robert Fishman’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how 4D Molecular Therapeutics’s whole pay program stands against its peers

  • 4D Molecular Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FDMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2021 (DEF 14A).

Free

Get Robert Fishman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robert Fishman compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$89,749
Bonus$50,000
Stock awards$0
Option awards$3,155,179
Non-equity incentive$44,875
Pension and deferred compensation$0
All other$0
Total$3,339,803

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 6, 2021, accession 0001193125-21-107762, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001193125-21-107762. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option240,000—$18.66

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Robert Fishman · this pageChief Medical Officer (5)$3,339,803
David KirnChief Executive Officer$701,533
August MorettiChief Financial Officer$632,762

The full 4D Molecular Therapeutics compensation record

free company brief

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Fishman's compensation dossier · One-time report. No refunds.